San Diego, CA-based Pathway Genomics, a clinical laboratory facilitating precision medicine through genetic testing and mobile healthcare applications has raised over $40 million in Series E funding. This brings the total investment into Pathway Genomics to over $130 million. Investors in this round of funding include IBM Watson, Pathway’s partner in the development of a mobile health application using artificial intelligence to provide personalized health and wellness guidance. The capital will be used to accelerate the company’s presence in the United States and beyond the 40 countries it currently serves internationally, capturing a growing share of the $38 billion global genomics market.
Founded in 2008, the precision medicine focused company has quickly established itself as a leader in the commercial healthcare landscape. Pathway Genomics’s core offering, a smartphone app leverages artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.
In addition, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health
